Ana Chopo-Pizarro

1 week ago | nature.com | Andria Mousa |Gina Cuomo-Dannenburg |Karen Barnes |Jaishree Raman |Ana Chopo-Pizarro |R. Matthew Chico | +2 more

AbstractSulfadoxine-pyrimethamine (SP) is recommended for perennial malaria chemoprevention in young children in high burden areas across Africa. Mutations in the dihydropteroate synthase (dhps) gene (437 G/540E/581 G) associated with sulfadoxine resistance vary regionally, but their effect on SP protective efficacy is unclear. We retrospectively analyse time to microscopy and PCR-confirmed re-infection in seven efficacy trials including 1639 participants in 12 sites across Africa.

Oct 24, 2024 | nature.com | Robert Mitchell |Akshayata Naidu |Pedro Aide |Ruth Aguilar |Claudia A Daubenberger |Carlota Dobaño | +1 more

AbstractRTS,S/AS01E, the first approved malaria vaccine, demonstrated moderate efficacy during the phase 3 pediatric trial. We previously investigated cell-mediated immune (CMI) responses following the primary 3-dose immunization and now report responses to the booster dose given 18 months later.